GlaxoSmithKline plc (NYSE: GSK) is a large market cap stock with a market cap of 106.3 B. It is in the Drug Manufacturers – Major industry and sector Healthcare, with a current P/E of 49.02, a forward P/E of 15.2 and EPS of 0.89. At a stock price of 43.7 (0.62%) it has a dividend yield of 4.49%.
EPS growth for the last five years have been -28.90%, more recently this last year it has grown by -89.20%. The next year growth is going to be about 1.24% and more long-term 13.10% after five years. EPS growth quarter over quarter is 271.90%. Sales growth for the past five years have been 0.40% and sales growth quarter over quarter is 18.50%.
For performance, GlaxoSmithKline plc the past week has seen a gain of -0.82%. For the last month performance for GlaxoSmithKline plc is 0.02%. While the last quarter is 2.77% and half year, 12.95%. Finally for the year, performance is 8.47%.
The 52-week high for GlaxoSmithKline plc, is at -4.12%, and for the 52-week low it comes to a value of 17.47%. The 20-day simple moving average is 0.37% and 6.49% for the 200-day simple moving average.
Volatility for the week is at 0.75%, and for the month it is 0.85%. GlaxoSmithKline plc, has a target price of 47.55.
In terms of debt, long term debt/equity is 8.52, and for total debt/equity GlaxoSmithKline plc has 10.7. The gross margin is 68.40%, while operating margin is 12.40%, the profit margin is 5.80%. The current ratio is 0.9 and the quick ratio is 0.6.
Insider ownership is at 0.20%, with instituitional ownership at 9.50%. GlaxoSmithKline plc has a payout ratio of 232.70%. With the total shares outstanding coming to 2447.54. The shares float is 2435.76, with the float short at 0.24%, with short ratio coming to 1.93.
In terms of returns, the return on assets see GlaxoSmithKline plc, get 2.90%, with its returns on investment at 8.60%. Return on equity is 188.80%. So will the investors see the target price of 47.55, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.
GlaxoSmithKline plc (NYSE: GSK)